Pethe Mohan, Yelwatkar Samir, Manchalwar Smita, Gujar Vijay
Department of Pharmacology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Wardha, Maharashtra, India.
Drug Res (Stuttg). 2017 Aug;67(8):485-492. doi: 10.1055/s-0043-109434. Epub 2017 May 18.
The current study sought to investigate antidiabetic, hypolipidimic, antioxidant and histopathological effects of floral extract of Hibiscus rosa sinensis in Alloxan induced Diabetes in rats. Study was conducted on 6 groups with 6 wistar rats in each group for the period of 4 weeks. Group I: served as normal control (NC), rats administered with gum acacia 1 ml daily, group II: consider as diabetic control (DC) treated with alloxon 150 mg/kg body wt. Whereas Hibiscus rosa-sinensis flower extract was given orally in group III (DE1), group IV (DE2), group V (DE3) at doses of 50, 100 and 200 mg/kg body weight dissolved in distilled water respectively. Group VI (DG) was given glibenclamide (5 mg/kg) as a standard drug and results were compared in reference to it. The results indicate that the test compound HEFHR (Hydroalcoholic extract of flower Hibiscus rosa-sinensis) has significant and sustained oral antidiabetic activity, comparable with the hypoglycemic effect of Glibenclamide and Sulphonylurea. Flower extract of HRS was more efficacious in lipid lowering effect and in antioxidative activity than glibenclamide. After 28 day treatment with flower extract, size of islets was significantly increased and necrosis and atrophy of islets were significantly improved; also increase in number and diameter of cell islets appeared to be regular as compared to the diabetic group. HEFHR possesses significant antidiabetic, hypolipidemic and antioxidant properties as well as regeneration of beta cells in rats. Further evaluation of HEFHR is in progress.
本研究旨在探讨木槿花提取物对四氧嘧啶诱导的糖尿病大鼠的抗糖尿病、降血脂、抗氧化及组织病理学作用。研究共6组，每组6只Wistar大鼠，为期4周。第一组：作为正常对照组（NC），大鼠每日灌胃1 ml阿拉伯胶；第二组：作为糖尿病对照组（DC），用150 mg/kg体重的四氧嘧啶处理。第三组（DE1）、第四组（DE2）、第五组（DE3）分别以50、100和200 mg/kg体重的剂量口服溶于蒸馏水的木槿花提取物。第六组（DG）给予格列本脲（5 mg/kg）作为标准药物，并以此为参照比较结果。结果表明，受试化合物HEFHR（木槿花花的水醇提取物）具有显著且持续的口服抗糖尿病活性，与格列本脲和磺酰脲类药物的降血糖效果相当。木槿花提取物在降低血脂和抗氧化活性方面比格列本脲更有效。用花提取物治疗28天后，胰岛大小显著增加，胰岛坏死和萎缩明显改善；与糖尿病组相比，胰岛细胞数量和直径的增加似乎也较为规律。HEFHR在大鼠中具有显著的抗糖尿病、降血脂和抗氧化特性以及β细胞再生作用。对HEFHR的进一步评估正在进行中。
